Tayner Rodriquez Garzon
Name: Tayner Rodriguez Garzon
Position: Research Fellow
Research Area: Cancer Drug Discovery
Qualifications: BSc (Hons), DipBiotech, PhD
Biography: Tayner completed his undergraduate degree in Bogota, Colombia, majoring in Marine Biology. In 2003 he moved to Australia, with a goal to become involved in medical research. He first completed a Diploma of Technology at the Southbank Institute of Technology, before undertaking a PhD in Molecular Genetics at Griffith University. His project investigated the evolution of genetic lineages using molecular genetic markers. Tayner joined the cancer research group of Discovery Biology in 2009, initially investigating prostate cancer pathways. He is a part of the Cancer Therapeutics initiative, performing cell based assays, which give abundant information with regards to cytotoxicity associated with candidate anti-cancer compounds. Tayner has been involved in different projects looking at targeting cancer cells with antimitotic compounds, antibody-drug conjugates, lamin-microtubules destabilising agents, tyrosine kinase signalling inhibitors and immunomodulatory strategies. More recently, he has been focused on understanding androgen receptor activation complexes to promote the development of better therapeutic agents. All this by using phenomic analysis to optimize and prioritize hits and/or develop target ID assays which are essential for drug discovery. Currently, he is leading a project using programmed ribosomal frameshifting to target mechanisms of multidrug resistance in cancer, by designing phenomic studies to recognise trends and relationships that otherwise will be difficult to uncover.
Discovery Biology
Publications:
Carrasco-Pozo C, Tan KN, Rodriguez T and Avery VM. The Molecular Effects of Sulforaphane and Capsaicin on Metabolism upon Androgen and Tip60 Activation of Androgen Receptor. International Journal of Molecular Science. 2019 Oct 29; 20(21): 5384.
Kaemmerer E, Rodriguez T, Lock A, Lovitt C and Avery VM. Innovative in vitro models for breast cancer drug discovery. Drug Discovery Today: Disease Models. [Invited review] 2017 March 18; 21: 11-16.
Conferences and Awards:
2022: Successfully selected to to take part in the Bridge Program (Commercialisation of new medicines) – Sydney/Gold Coast, Australia
2022: Speaker – Griffith Cancer Research Network Symposium - Brisbane, Australia
2019: Speaker at the 6th GRIDD/SIMM 2019 International Symposium – Brisbane, Australia
2018: Functional High Throughput Technologies Australia (Speaker) – Canberra, Australia
2018: CTx conference sponsor
2018: LONZA travel grant
2015: 5th Munich Biomarker Conference – 15 points to Continuing Medical Education (CME) – Munich, Germany
2015: Oncology Drug Development in Practice (ODDP), Award (travel and fees) – Amsterdam, Netherlands
2015: Queensland epithelial-mesenchymal transition (EMT) Symposium – Brisbane, Australia
